Government Agencies

Pharmalot By Rachel Cohrs and Ed Silverman

Biden administration poised to give pharmacies a major lobbying win

First Opinion By Jeffrey A. Lieberman

The case for Califf: Don’t let politics prevent confirmation of best FDA commissioner candidate

Matt's Take By Matthew Herper

Robert Califf is a fervent believer in data. At the FDA, will that be enough?

Politics By Nicholas Florko

FDA’s vaccines and biologics chief talks Covid-19, 2022 priorities, and getting back to gene, cell therapy review

First Opinion By Vinay Prasad

At a time when the U.S. needed Covid-19 dialogue between scientists, Francis Collins moved to shut it down

Pharmalot By Ed Silverman

FDA rebukes Endo for ‘anticompetitive practices’ and asks FTC to investigate

Politics By Nicholas Florko

Califf sails through confirmation hearing for FDA job, despite tensions over opioids

First Opinion By Kathleen “Cook” Uhl

FDA’s outdated Birth Control Guide blocks access to the innovations the agency has approved

Pharmalot By Ed Silverman

Feeling remote: Coalition of pharma regulators looks to complement on-site inspections beyond Covid

Kassemine Pass Covid-19 leaders leadership

First Opinion By Steve Brozak

The U.S. is at a Kasserine Pass moment for Covid leaders

First Opinion By Tahir Amin and Priti Krishtel

Solving the U.S. drug pricing crisis starts with a crucial confirmation hearing

First Opinion By Kushal Kadakia and Harlan M. Krumholz

Reforms needed for FDA’s regulation of medical devices

Politics By Nicholas Florko

Califf, nominee to lead FDA, asks Woodcock to stay in leadership role if he’s confirmed

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron

nursing homes resident-to-resident incidents

First Opinion By Eilon Caspi

Resident-to-resident incidents are a hidden source of harm in nursing homes. They shouldn’t be

Pharmalot By Ed Silverman

FDA is urged to disqualify a hospital review board and two doctors over clinical trial missteps

Pharmalot By Ed Silverman

When FDA rattles its sabre, drug makers and universities start reporting overdue trial results

Politics By Nicholas Florko

Biden taps Califf to head FDA — an agency where he has plenty of unfinished business

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Moderna v. NIH, psilocybin as a medicine, & the cultural intake of pharma CEOs

Opinions+ By Andrei Iancu and David Kappos

Why does the FDA want to stop improving medicines via patent ‘areas of concern’?

Pharmalot By Ed Silverman

New court rulings add to the confusing and controversial dispute over a U.S. drug discount program

First Opinion By Haider J. Warraich

I’ve worked with Robert Califf. He is the leader the FDA needs

Biotech By Nicholas Florko

The loudest physician proponents of Aduhelm have all taken money from Biogen

Pharmalot By Ed Silverman

U.S. bid to force drug makers to offer discounts to some hospitals was ‘arbitrary and capricious,’ judge rules

Health By Megan Molteni

Most Read

Deaths of despair: the unrecognized tragedy of working class immiseration

Nuclear Regulatory Commission’s foot-dragging on patient irradiation suggests regulatory capture

3 pharma trends to watch in 2022

Top regulator says need for Omicron vaccine depends on staying power of variant

The Fifth Circuit Court got the science wrong on OSHA’s vaccination mandate

Rochelle Walensky said she’d ‘fix’ the CDC, but nine months in, she’s faltering

On Covid-19 booster shots, the FDA has overstepped its role

A natural pandemic has been terrible. A synthetic one would be even worse

All Coverage

Biden administration poised to give pharmacies a major lobbying win

The case for Califf: Don’t let politics prevent confirmation of best FDA commissioner candidate

Robert Califf is a fervent believer in data. At the FDA, will that be enough?

FDA’s vaccines and biologics chief talks Covid-19, 2022 priorities, and getting back to gene, cell therapy review

At a time when the U.S. needed Covid-19 dialogue between scientists, Francis Collins moved to shut it down

FDA rebukes Endo for ‘anticompetitive practices’ and asks FTC to investigate

Califf sails through confirmation hearing for FDA job, despite tensions over opioids

FDA’s outdated Birth Control Guide blocks access to the innovations the agency has approved

Feeling remote: Coalition of pharma regulators looks to complement on-site inspections beyond Covid

The U.S. is at a Kasserine Pass moment for Covid leaders

Solving the U.S. drug pricing crisis starts with a crucial confirmation hearing

Reforms needed for FDA’s regulation of medical devices

Califf, nominee to lead FDA, asks Woodcock to stay in leadership role if he’s confirmed

Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron

Resident-to-resident incidents are a hidden source of harm in nursing homes. They shouldn’t be

FDA is urged to disqualify a hospital review board and two doctors over clinical trial missteps

When FDA rattles its sabre, drug makers and universities start reporting overdue trial results

Biden taps Califf to head FDA — an agency where he has plenty of unfinished business

Listen: Moderna v. NIH, psilocybin as a medicine, & the cultural intake of pharma CEOs

Why does the FDA want to stop improving medicines via patent ‘areas of concern’?

New court rulings add to the confusing and controversial dispute over a U.S. drug discount program

I’ve worked with Robert Califf. He is the leader the FDA needs

The loudest physician proponents of Aduhelm have all taken money from Biogen

U.S. bid to force drug makers to offer discounts to some hospitals was ‘arbitrary and capricious,’ judge rules

Public-private partnership launched to accelerate gene therapies for rare diseases

government agencies

Most Read

All Coverage